Ownership and insider activity for Alkermes plc (ALKS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Price
| Price | $46.07 |
| Market Cap | $7.7B |
| Exchange | NASDAQ |
| Country | IE |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-03 | Gaffin David Joseph | S-Sale | 2,034 | $98K |
| 2026-09-01 | Hopkinson Craig C. | M-Exempt | 5,000 | $123K |
| 2026-09-01 | Hopkinson Craig C. | S-Sale | 9,000 | $423K |
| 2026-09-01 | Hopkinson Craig C. | M-Exempt | 5,000 | $123K |
| 2026-08-17 | Nichols Christian Todd | S-Sale | 6,912 | $340K |
| 2026-08-17 | Nichols Christian Todd | S-Sale | 664 | $33K |
| 2026-08-05 | Jackson Blair Curtis | A-Award | 124,305 | $6.2M |
| 2026-08-05 | Jackson Blair Curtis | A-Award | 93,229 | $4.6M |
| 2026-08-03 | snyderman nancy lynn MD | M-Exempt | 16,524 | $772K |
| 2026-08-03 | snyderman nancy lynn MD | M-Exempt | 27,948 | $1.3M |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $186.4M | $191.3M | $266.8M | $203.8M | $273.0M | $337.5M | $292.5M | $457.5M | $291.1M | $1.12B |
| Short-term Investments | $310.9M | $242.2M | $272.5M | $331.2M | $362.1M | $198.8M | $316.0M | $316.0M | $460.5M | $199.6M |
| Receivables | $191.1M | $233.6M | $300.5M | $265.5M | $289.5M | $326.6M | $296.9M | $333.2M | $389.5M | $334.0M |
| Inventory | $63.0M | $93.3M | $90.2M | $101.8M | $125.7M | $150.3M | $181.4M | $186.4M | $182.9M | $196.6M |
| Total Current Assets | $912.6M | $966.1M | $983.3M | $962.0M | $1.11B | $1.06B | $1.13B | $1.49B | $1.42B | $1.93B |
| Property, Plant & Equipment | $264.8M | $284.7M | $310.0M | $374.5M | $481.7M | $456.7M | $320.5M | $318.4M | $311.8M | $298.9M |
| Goodwill | $92.9M | $92.9M | $92.9M | $92.9M | $92.9M | $92.9M | $83.0M | $83.0M | $83.0M | 0 |
| Intangible Assets | $318.2M | $256.2M | $191.0M | $150.6M | $111.2M | $74.0M | $37.7M | $2.0M | $890000 | $83.8M |
| Total Assets | $1.73B | $1.80B | $1.83B | $1.81B | $1.95B | $2.02B | $1.96B | $2.14B | $2.06B | $2.53B |
| Accounts Payable | $46.3M | $55.5M | $39.8M | $54.3M | $46.0M | $55.7M | $32.8M | $65.6M | $45.6M | $108.0M |
| Short-term Debt | $3.0M | $3.0M | $2.8M | $2.8M | $2.8M | $3.0M | $3.0M | $3.0M | 0 | $6.7M |
| Total Current Liabilities | $212.0M | $291.1M | $339.8M | $391.1M | $438.3M | $471.3M | $497.7M | $520.2M | $465.2M | $543.4M |
| Long-term Debt | $280.7M | $278.4M | $276.5M | $274.3M | $272.1M | $292.8M | $290.3M | $287.7M | 0 | 0 |
| Total Liabilities | $516.9M | $594.4M | $653.7M | $720.0M | $882.7M | $911.9M | $920.2M | $933.5M | $590.6M | $711.0M |
| Retained Earnings | -$947.9M | -$1.04B | -$1.19B | -$1.38B | -$1.49B | -$1.54B | -$1.70B | -$1.34B | -$976.5M | -$734.8M |
| Total Equity | $1.21B | $1.20B | $1.17B | $1.09B | $1.07B | $1.11B | $1.04B | $1.20B | $1.46B | $1.82B |
| Total Debt | $283.7M | $281.4M | $279.3M | $290.9M | $410.2M | $416.2M | $379.4M | $372.2M | $75.5M | $70.0M |
| Net Debt | -$335.5M | -$309.3M | -$260.0M | -$244.0M | -$224.9M | -$120.1M | -$229.0M | -$401.3M | -$676.1M | -$1.25B |
| Working Capital | $700.6M | $674.9M | $643.5M | $570.9M | $672.7M | $590.9M | $632.6M | $965.3M | $950.2M | $1.39B |
Financial Health
| Debt / Equity | 0.87 |
| Current Ratio | 2.30 |
Profitability
| Gross Margin | 84.56% |
| Operating Margin | 7.03% |
| Net Margin | 3.97% |
Related companies: ACAD · ACLX · AKRO · ARWR · CRSP · KYMR · PCVX
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of ALKS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks